Drug Approval | May 12, 2022
USFDA approves Lilly and Incyte's Olumiant to treat hospitalised patients with Covid-19
Olumiant is the first and only JAK inhibitor USFDA-approved for the treatment of Covid-19
Olumiant is the first and only JAK inhibitor USFDA-approved for the treatment of Covid-19
Deucravacitinib is currently under regulatory review in multiple regions, including the U.S., Europe and Japan, and would be the first selective allosteric tyrosine kinase 2 (TYK2) inhibitor approved for the treatment of any disease
With launches, continuing momentum in India, other branded markets and a pick-up in the US, Ajanta would deliver 12% revenue/PAT growth each over FY22-24
CB03 is a candidate drug for the treatment of refractory epilepsy, independently developed by Zhimeng
The company exports mobile surgery equipment to over 100 countries from Pune
The unit is an oral manufacturing facility at Jedcherla, Hyderabad
The new logo is a refreshing change from the version that has served Hetero well for three decades. And yet its reflection can be seen in the new version
The partners also aim to expand their work to Latin America for the first time
Company's net income rose by 57.5 percent to 3.291 billion euros in Q1
NWSS works with public health departments across the country to track SARS-CoV-2 levels in wastewater so communities can act quickly to prevent the spread of Covid-19.
Subscribe To Our Newsletter & Stay Updated
